The Effectiveness Of Lipids Derived From Pseudomonas Putida Bacteria In The Formulation Of Nanoliposomes Enhances The Delivery Of Vincristine For The Treatment Of Prostate Cancer.

IF 3.7 4区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

IEEE Transactions on NanoBioscience Pub Date : 2025-07-23 DOI:10.1109/TNB.2025.3591912

Saba Jalilian, Mohammad Javad Hoseinifar, Zahra Asadi, Elham Arkan, Nahid Moarrefzadeh, Faranak Aghaz

{"title":"The Effectiveness Of Lipids Derived From Pseudomonas Putida Bacteria In The Formulation Of Nanoliposomes Enhances The Delivery Of Vincristine For The Treatment Of Prostate Cancer.","authors":"Saba Jalilian, Mohammad Javad Hoseinifar, Zahra Asadi, Elham Arkan, Nahid Moarrefzadeh, Faranak Aghaz","doi":"10.1109/TNB.2025.3591912","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) presents a significant challenge globally due to drug resistance and the severe side effects linked to conventional treatments. In this study, we developed vincristine-loaded nanoliposome-based lipids derived from Pseudomonas putida bacteria (VCR-NLPs) utilizing a thin-layer method. The produced bacteria-lipid-based nanoliposomes represented a critical advancement in drug delivery, offering superior drug encapsulation, controlled release, and enhanced biocompatibility. VCR-NLPs were thoroughly characterized, displaying a spherical morphology with an average particle size of approximately 145 nm, a final zeta potential of -13.1 mV, and a biphasic release profile of VCR. The formulation exhibited efficient drug loading, with 50% release at pH 7.4 and 70% at pH 6, reflecting pH-responsive release behavior tailored to the acidic tumor microenvironment, thereby enhancing therapeutic efficacy. Our flow-cytometric analysis confirmed an efficient induction of late-stage apoptosis in PC3 cells after treatment with VCR-NLPs. These findings suggest that Pseudomonas putida-Lipid-based VCR-NLPs offer a promising nanocarrier system for targeted prostate cancer therapy, due to inducing controlled release of VCR and improving biocompatibility of it, for clinical treatments.</p>","PeriodicalId":13264,"journal":{"name":"IEEE Transactions on NanoBioscience","volume":"PP ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IEEE Transactions on NanoBioscience","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1109/TNB.2025.3591912","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer (PCa) presents a significant challenge globally due to drug resistance and the severe side effects linked to conventional treatments. In this study, we developed vincristine-loaded nanoliposome-based lipids derived from Pseudomonas putida bacteria (VCR-NLPs) utilizing a thin-layer method. The produced bacteria-lipid-based nanoliposomes represented a critical advancement in drug delivery, offering superior drug encapsulation, controlled release, and enhanced biocompatibility. VCR-NLPs were thoroughly characterized, displaying a spherical morphology with an average particle size of approximately 145 nm, a final zeta potential of -13.1 mV, and a biphasic release profile of VCR. The formulation exhibited efficient drug loading, with 50% release at pH 7.4 and 70% at pH 6, reflecting pH-responsive release behavior tailored to the acidic tumor microenvironment, thereby enhancing therapeutic efficacy. Our flow-cytometric analysis confirmed an efficient induction of late-stage apoptosis in PC3 cells after treatment with VCR-NLPs. These findings suggest that Pseudomonas putida-Lipid-based VCR-NLPs offer a promising nanocarrier system for targeted prostate cancer therapy, due to inducing controlled release of VCR and improving biocompatibility of it, for clinical treatments.

查看原文本刊更多论文

从恶臭假单胞菌中提取的脂质在纳米脂质体制剂中的有效性增强了长春新碱治疗前列腺癌的递送。

前列腺癌（PCa）由于耐药性和与常规治疗相关的严重副作用，在全球范围内提出了重大挑战。在这项研究中，我们利用薄层法从恶臭假单胞菌（vcr - nlp）中提取了含有长春新碱的纳米脂质体。所产生的细菌脂质纳米脂质体代表了药物传递的关键进步，提供了优越的药物包封，控释和增强的生物相容性。对VCR- nlp进行了全面表征，显示出平均粒径约为145 nm的球形形貌，最终zeta电位为-13.1 mV，以及VCR的双相释放谱。该制剂具有高效的载药量，在pH 7.4和pH 6下分别有50%和70%的释药，反映了针对酸性肿瘤微环境的pH响应释药行为，从而提高了治疗效果。我们的流式细胞术分析证实了vcr - nlp治疗后PC3细胞晚期凋亡的有效诱导。这些结果表明，以恶臭假单胞菌-脂质为基础的VCR- nlp可诱导VCR的控释并提高其生物相容性，为前列腺癌靶向治疗提供了一种很有前景的纳米载体体系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

IEEE Transactions on NanoBioscience 工程技术-纳米科技

CiteScore

7.00

自引率

5.10%

发文量

197

审稿时长

>12 weeks

期刊介绍： The IEEE Transactions on NanoBioscience reports on original, innovative and interdisciplinary work on all aspects of molecular systems, cellular systems, and tissues (including molecular electronics). Topics covered in the journal focus on a broad spectrum of aspects, both on foundations and on applications. Specifically, methods and techniques, experimental aspects, design and implementation, instrumentation and laboratory equipment, clinical aspects, hardware and software data acquisition and analysis and computer based modelling are covered (based on traditional or high performance computing - parallel computers or computer networks).